
According to data from Benzinga Pro, during Q1, Sage Therapeutics's (NASDAQ:SAGE) reported sales totaled $1.58 million. Despite a 2.13% increase in earnings, the company posted a loss of $122.06 million. In Q4, Sage Therapeutics brought in $1.64 million in sales but lost $124.71 million in earnings.